Imran Dar, MD
Interventional Cardiology · Houston, TXNPI 1124228093
Payments from drug & device makers
Across 286 payments — averaging $87.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Medtronic$2K
- Abbott$1K
- Johnson & Johnson$965
- Amgen$603
- Novartis$576
- plus $2K from 32 others
Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$300
What the payments were for
- Travel & lodging$86212%
- Food & beverage$6,32688%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $18,011 |
| Medtronic(2 entities) | 28 | $1,539 |
| Abbott | 21 | $1,011 |
| Johnson & Johnson | 62 | $965 |
| Amgen | 30 | $603 |
| Novartis | 29 | $576 |
| Boston Scientific | 10 | $275 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $214 |
| Biotronik Inc. | 8 | $184 |
| Cleerly, Inc. | 4 | $157 |
| Chiesi USA, Inc. | 8 | $145 |
| Myocardial Solutions, Inc. | 1 | $135 |
| Boehringer Ingelheim | 6 | $128 |
| Esperion Therapeutics, Inc. | 7 | $122 |
| Atricure, Inc. | 1 | $107 |
| Novo Nordisk | 5 | $106 |
| Pfizer | 5 | $94 |
| Philips North America LLC | 2 | $85 |
| Merck | 3 | $47 |
| Lilly USA, LLC | 2 | $45 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| G Medical Diagnostic Services, Inc. | 2 | $29 |
| Preventice Services, LLC | 1 | $29 |
| Angiodynamics, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Abiomed | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Heartflow, Inc. | 1 | $21 |
| Shockwave Medical, Inc | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| EKOS Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,976 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 247 | $284,055 |
| EliquisApixaban | 208 | $260,472 |
| BrilintaTicagrelor | 102 | $89,900 |
| EntrestoSacubitril/Valsartan | 49 | $75,425 |
| Repatha SureclickEvolocumab | 39 | $48,457 |
| FarxigaDapagliflozin Propanediol | 20 | $25,544 |
| Repatha SyringeEvolocumab | 12 | $17,296 |
| MounjaroTirzepatide | 14 | $16,685 |
| NexletolBempedoic Acid | 23 | $13,633 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $10,018 |
| Ranolazine ErRanolazine | 124 | $9,536 |
| Rosuvastatin Calcium | 344 | $5,512 |
| Icosapent Ethyl | 13 | $5,150 |
| Atorvastatin Calcium | 391 | $4,170 |
| Losartan Potassium | 366 | $3,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $965 | $284,055247 claims |
| PfizerEliquis | $94 | $260,472208 claims |
| AstraZenecaBrilinta, Farxiga | $18,011 | $115,444122 claims |
| NovartisEntresto | $576 | $75,42549 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $122 | $23,65137 claims |
| Lilly USA, LLCMounjaro | $45 | $16,68514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.